Hormones after breast cancer publication receives honor

Linda Brent, PhD

Executive Director, Parsemus Foundation

A new research study found that hormone therapy following breast cancer had significant benefits in terms of greater physical activity, improved cognition, and better cardiovascular and bone health in a mouse model. The current treatment for women after hormone-sensitive breast cancer is estrogen-blocking aromatase inhibitors, a nearly opposite treatment to hormone therapy. Not only did the right combination of hormones provide better outcomes in terms of cardiovascular and bone measures, but were also more effective against breast cancer. The research published in Reproductive Biology and Endocrinology by lead scientist Dr. Lakshmanaswamy and funded by Parsemus Foundation has been drawing the attention of scientists and interested public alike. BioMed Central recently recognized the paper as a “Highly Accessed” article.

We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today